The failure in a key pipeline candidate suggests potential challenges in Insmed's development strategy. Traders should assess the impact on overall pipeline value and watch for any management commentary on reallocation of resources to other programs. Consider this setback in context of the company's $35.4B market cap and recent insider selling activity.
Price Chart
Executive Summary
Insmed announced that its Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa (HS) failed to meet primary or secondary efficacy endpoints, with both treatment arms showing inferior results to placebo. The company will discontinue development of brensocatib for HS, representing a significant setback for this pipeline candidate.
Key Facts
- Phase 2b CEDAR study failed to meet primary or secondary efficacy endpoints for brensocatib in hidradenitis suppurativa
- At Week 16, brensocatib 10 mg and 40 mg arms showed 45.5% and 40.3% reduction in abscess and inflammatory nodule count, respectively, compared to 57.1% reduction in placebo arm
- Insmed will discontinue development of brensocatib for HS indication
- Safety profile was consistent with previous studies with no new safety signals identified
Financial Impact
Elimination of potential future revenue from brensocatib in HS, with immediate R&D cost savings from discontinued program
Risk Factors
- Reputational damage to Insmed's clinical development capabilities
- Potential questions about the viability of other pipeline candidates
- Downward pressure on stock price due to failed clinical trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-013659 |
| Document: ef20070042_ex99-1.htm | 0001140361-26-013659 |
| Document: 0001140361-26-013659-index-headers.html | 0001140361-26-013659 |
| Document: 0001140361-26-013659-index.html | 0001140361-26-013659 |
| Document: 0001140361-26-013659.txt | 0001140361-26-013659 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $130.66 $119.92 | ▼ −8.22% | ▼ −6.70% | $111.34 (−14.79%) |
Aug 12, 2026 7w ago | Insider Cluster | $126.33 $129.41 | ▲ +2.44% | ▲ +4.19% | $111.34 (−11.87%) |
Aug 6, 2026 8w ago | 8-K | $132.55 $126.68 | ▼ −4.43% | ▼ −5.03% | $111.34 (−16.00%) |
Jul 24, 2026 10w ago | Institutional Cluster | $106.92 $125.77 | ▲ +17.63% | ▲ +14.00% | $111.34 (+4.13%) |
Jul 21, 2026 10w ago | ANALYST-UPGRADE | $108.62 $128.46 | ▲ +18.27% | ▲ +15.70% | $111.34 (+2.50%) |
Jul 16, 2026 11w ago | 8-K | $107.46 $126.33 | ▲ +17.56% | ▲ +13.94% | $111.34 (+3.61%) |
Jun 26, 2026 13w ago | Insider Cluster | $104.74 $106.92 | ▲ +2.08% | ▲ +2.36% | $111.34 (+6.30%) |
Jun 5, 2026 16w ago | Insider Cluster | $94.17 $111.54 | ▲ +18.45% | ▲ +16.81% | $111.34 (+18.23%) |
Jun 5, 2026 16w ago | Insider Cluster | $94.17 $111.54 | ▲ +18.45% | ▲ +16.81% | $111.34 (+18.23%) |
May 15, 2026 19w ago | S-3ASR | $107.15 $95.52 | ▼ −10.85% | ▼ −12.44% | $111.34 (+3.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access